Filtered By:
Specialty: Cancer & Oncology
Condition: Heart Attack

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 138 results found since Jan 2013.

Borderline operability in hepatectomy patients is associated with higher rates of failure to rescue after severe complications
ConclusionsHepatectomy patients meeting BL criteria have an overall post‐hepatectomy mortality rate that is triple that of non‐BL patients. With less clinical reserve, BL patients who suffer SC are at greater risk of post‐hepatectomy death. J. Surg. Oncol. © 2016 Wiley Periodicals, Inc.
Source: Journal of Surgical Oncology - November 2, 2016 Category: Cancer & Oncology Authors: Bradford J. Kim, Ching ‐Wei D. Tzeng, Amanda B. Cooper, Jean‐Nicolas Vauthey, Thomas A. Aloia Tags: Research Article Source Type: research

The effect of the severity of obstructive sleep apnea syndrome on telomere length.
In conclusion, our study indicates the presence of an association between LTL and OSAS and a significant impact of severity of OSAS in telomeres shortening. PMID: 27690344 [PubMed - as supplied by publisher]
Source: Oncotarget - October 2, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study
Abstract We critically examined long-term cardiovascular (CV) outcomes and overall survival (OS) of breast cancer (BC) patients who had cardiotoxicity during adjuvant trastuzumab treatment requiring discontinuation in a population-based sample. This was a retrospective cohort of early-stage BC patients diagnosed before 2010 and treated with trastuzumab in Ontario. Patients were stratified based on trastuzumab doses received: 1–8, 9–15, ≥16 (therapy completion). Time-dependent multivariable Cox models were used to analyze primary endpoint OS, and the following composite endpoints: hospitalization/emergency ro...
Source: Breast Cancer Research and Treatment - June 5, 2016 Category: Cancer & Oncology Source Type: research

Breast Cancer Meds Won't Raise Chances of Heart Attack, Stroke, Study Suggests
Title: Breast Cancer Meds Won't Raise Chances of Heart Attack, Stroke, Study SuggestsCategory: Health NewsCreated: 4/21/2016 12:00:00 AMLast Editorial Review: 4/22/2016 12:00:00 AM
Source: MedicineNet Cancer General - April 22, 2016 Category: Cancer & Oncology Source Type: news

Breast Cancer Meds Won’t Raise Chances of Heart Attack, Stroke, Study Suggests
But there was a slightly increased risk of less serious heart problems
Source: The Doctors Lounge - Oncology - April 20, 2016 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Endocrinology, Gynecology, Oncology, Pharmacy, News, Source Type: news

Task Force Releases Recommendations on Aspirin to Prevent Colon Cancer, Heart Disease
By Stacy SimonRESOURCES: Aspirin and Cancer Prevention: What the Research Really Shows The United States Preventive Services Task Force (USPSTF) has published new recommendations about aspirin to help prevent cardiovascular disease (heart attacks and strokes) and colorectal cancer (commonly called colon cancer).The USPSTF says people who are ages 50-59 years, who have at least a 10% risk of developing cardiovascular disease within the next 10 years, and who have no increased risk for bleeding should take low-dose aspirin regularly to help prevent heart attack, stroke, and colon cancer. Candidates should also have a l...
Source: American Cancer Society :: News and Features - April 11, 2016 Category: Cancer & Oncology Tags: Colon/Rectum Cancer Source Type: news

USPSTF publishes recommendation on taking aspirin to prevent heart attack, stroke, and colorectal cancer
(American College of Physicians) The US Preventive Services Task Force recommends that people who are 50-69 years old, have increased risk of cardiovascular disease (CVD), and who are not at increased risk for bleeding, consider taking aspirin for primary prevention of CVD and colorectal cancer. The full recommendation and evidence reviews are published in Annals of Internal Medicine.
Source: EurekAlert! - Cancer - April 11, 2016 Category: Cancer & Oncology Source Type: news

Progerin impairs chromosome maintenance by depleting CENP-F from metaphase kinetochores in Hutchinson-Gilford progeria fibroblasts.
In this study, we investigated whether progerin elicits spatiotemporal deviations in mitotic processes in HGPS fibroblasts. We analyzed the nuclear distribution of endogenous progerin during mitosis in relation to components of the nuclear lamina, nuclear envelope (NE) and nuclear pores. We found that progerin caused defects in chromosome segregation as early as metaphase, delayed NE reformation and trapped lamina components and inner NE proteins in the endoplasmic reticulum at the end of mitosis. Progerin displaced the centromere protein F (CENP-F) from metaphase chromosome kinetochores, which caused increased chromatin l...
Source: Oncotarget - March 27, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data
Conclusion Elderly patients with CML had greater mortality and greater rates of MI, stroke, PE, and PAD than did noncancer patients. The event rates were not elevated among the TKI-treated (primary imatinib) patients, suggesting that the VE risk in these patients with CML was driven primarily by the underlying factors associated with CML. Micro-Abstract Tyrosine-kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can be associated with vascular events (VEs). We examined the event rates and mortality among elderly patients with and without CML using linked cancer registry and Medicare claims data from 2003 t...
Source: Clinical Lymphoma Myeloma and Leukemia - March 21, 2016 Category: Cancer & Oncology Source Type: research

Effect of folic acid supplementation on cancer risk among adults with hypertension in China: A randomized clinical trial
This article is protected by copyright. All rights reserved.
Source: International Journal of Cancer - March 17, 2016 Category: Cancer & Oncology Authors: Xianhui Qin, Lin Shen, Rong Zhang, Youbao Li, Xiaobin Wang, Binyan Wang, Xiaodong Jiang, Hua Jiang, Yu Lei, Fan Fan Hou, Jin Gu, Yong Huo Tags: Research Article Source Type: research

Clopidogrel-induced refractory thrombotic thrombocytopenic purpura successfully treated with rituximab
Publication date: Available online 2 December 2015 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Sara Khodor, Miguel Castro, Colin McNamara, Chakra P. Chaulagain Thrombotic thrombocytopenic purpura (TTP) is a multisystem disorder characterized by microvascular aggregation of platelets and fibrin strands causing thrombocytopenia, microangiopathic hemolytic anemia, and organ dysfunction. TTP can develop as a result of a deficiency in ADAMTS13 enzyme activity due to either a genetic defect or, more commonly, the development of anti-ADAMTS13 autoantibodies. TTP can also be associated with pregnancy, organ t...
Source: Hematology Oncology and Stem Cell Therapy - March 7, 2016 Category: Cancer & Oncology Source Type: research

Mortality and Vascular Events Among Elderly Patients with Chronic Myeloid Leukemia (CML): A Retrospective Analysis of Linked Seer-Medicare Data
Conclusions Elderly CML patients had higher mortality and higher rates of MI, stroke, PE and PAD than non-cancer patients. Event rates were not elevated among TKI-treated (primary imatinib) patients, suggesting that VE risk in these CML patients was driven primarily by underlying factors associated with CML. Teaser TKI treatment of CML may be associated with vascular events (VE). We examined event rates and mortality among elderly CML and non-cancer patients using linked cancer registry and Medicare claims data, 2003-2010. CML patients had higher mortality and VE rates. Rates were not elevated among TKI (primarily imatinib...
Source: Clinical Lymphoma Myeloma and Leukemia - February 7, 2016 Category: Cancer & Oncology Source Type: research

Study: Nicotine Patch Works as Well as Chantix to Help Quit Smoking
This study confirms that FDA-approved medications are effective in helping smokers quit,” said Lee Westmaas, PhD, American Cancer Society director of tobacco control research. “Smokers should seriously consider using medications if they are finding it difficult to quit without any help. The most effective approach to quitting is using medications in combination with counseling such as from a quit-line.”RESOURCES: How to Quit Smoking Quit-smoking medicationsResearch shows that using a medication to help you quit smoking can double your chances of being successful.The US Food and Drug Administration (...
Source: American Cancer Society :: News and Features - February 2, 2016 Category: Cancer & Oncology Tags: Smoking/Tobacco Source Type: news

Cancer is associated with intraoperative and postprocedural complications and disorders
Conclusion The present study indicates that cancer increases the risk of IPCs and may reduce the clinical benefits of surgery.
Source: Journal of Cancer Research and Clinical Oncology - December 9, 2015 Category: Cancer & Oncology Source Type: research